APA (7th ed.) Citation

AH, T., S, J., P, J., S, J., JM, P., X, S., . . . JC, B. (2014). Infliximab for intensification of primary therapy for Kawasaki disease: A phase 3 randomised, double-blind, placebo-controlled trial. Lancet (London, England), 383(9930), 1731. https://doi.org/10.1016/S0140-6736(13)62298-9

Chicago Style (17th ed.) Citation

AH, Tremoulet, et al. "Infliximab for Intensification of Primary Therapy for Kawasaki Disease: A Phase 3 Randomised, Double-blind, Placebo-controlled Trial." Lancet (London, England) 383, no. 9930 (2014): 1731. https://doi.org/10.1016/S0140-6736(13)62298-9.

MLA (9th ed.) Citation

AH, Tremoulet, et al. "Infliximab for Intensification of Primary Therapy for Kawasaki Disease: A Phase 3 Randomised, Double-blind, Placebo-controlled Trial." Lancet (London, England), vol. 383, no. 9930, 2014, p. 1731, https://doi.org/10.1016/S0140-6736(13)62298-9.